Skip to main content Back to Top
Advertisement

9/5/2023

Clindamycin Phosphate Injection

Products Affected - Description

    • Cleocin injection, Pfizer, 150 mg/mL, 2 mL vial, 25 count, NDC 00009-0870-26
    • Cleocin injection, Pfizer, 150 mg/mL, 4 mL vial, 25 count, NDC 00009-0775-26
    • Cleocin injection, Pfizer, 150 mg/mL, 6 mL vial, 25 count, NDC 00009-0902-18
    • Cleocin injection, Pfizer, 150 mg/mL, 60 mL bulk vial, 5 count, NDC 00009-0728-09
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 2 mL vial, 25 count, NDC 72611-0634-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 4 mL vial, 25 count, NDC 72611-0639-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 6 mL vial, 25 count, NDC 72611-0642-25 - discontinued
    • Clindamycin phosphate injection, Almaject, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 72611-0645-55 - discontinued
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9545-50
    • Clindamycin phosphate injection, Baxter, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3410-50
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9549-50
    • Clindamycin phosphate injection, Baxter, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3612-50
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 0.9% sodium chloride premixed container, 24 count, NDC 00338-9553-50
    • Clindamycin phosphate injection, Baxter, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00338-3814-50
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 2 mL vial, 25 count, NDC 25021-0115-02
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 4 mL vial, 25 count, NDC 25021-0115-04
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 6 mL vial, 25 count, NDC 25021-0115-06
    • Clindamycin phosphate injection, Sagent, 150 mg/mL, 60 mL bulk vial, 1 count, NDC 25021-0115-51
    • Clindamycin phosphate injection, Sandoz, 300 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3288-09
    • Clindamycin phosphate injection, Sandoz, 600 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3289-09
    • Clindamycin phosphate injection, Sandoz, 900 mg/50 mL, in 5% dextrose premixed container, 24 count, NDC 00781-3290-09

Reason for the Shortage

    • Almaject discontinued clindamycin injection in 2023.
    • Baxter has clindamycin injection on shortage due to third party supplier issue.
    • Pfizer has clindamycin injection on shortage due to manufacturing delays.
    • Sagent has clindamycin injection on shortage due to manufacturing delays.
    • Sandoz did not provide a reason for the shortage.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Baxter has clindamycin 300 mg/50 mL, 600 mg/50 mL, and 900 mg/50 mL premixed bags in 0.9% sodium chloride on a limited allocation. The 300 mg/50 mL, 600 mg/50 mL, and 900 mg/50 mL premixed bags in 5% dextrose are on a limited allocation.
    • Pfizer has Cleocin 150 mg/mL 2 mL and 60 mL vials on back order and the company estimates a release date of September 2023. The 4 mL and 60 mL vials are available in limited supply.
    • Sagent has clindamycin phosphate 150 mg/mL 2 mL, 4 mL, 6 mL, and 60 mL vials on back order and the company cannot estimate a release date.
    • Sandoz has clindamycin 300 mg/50 mL, 600 mg/50 mL premixed bags, and 900 mg/50 mL premixed bags on back order and the company cannot estimate a release date.

Updated

Updated September 5, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 13, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.